PIK3CA and non-small cell lung carcinoma: The combination of rapamycin and docetaxel was found to synergistically inhibit the growth of lung cancer cells [127] and also the addition of rapamycin to PI3K inhibitors LY294002 and NVP-BKM120 resulted in synergistic act against NSCLC specimens [128], suggesting the possible efficacy of using rapamycin in combination with chemotherapy or other targeted agents in the treatment of lung cancer.